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Abstract
Backround: A meta-analysis combining results from three genome-wide association studies and followed by large-scale
replication identified six novel type 2 diabetes loci. Subsequent studies of the effect of these variants on estimates of the
beta-cell function and insulin sensitivity have been inconclusive. We examined these variants located in or near the JAZF1
(rs864745), THADA (rs7578597), TSPAN8 (rs7961581), ADAMTS9 (rs4607103), NOTCH2 (rs10923931) and the CDC123/CAMK1D
(rs12779790) genes for associations with measures of pancreatic beta-cell function and insulin sensitivity.
Methodology/Results: Oral and intravenous glucose stimulated insulin release (n=849) and insulin sensitivity (n=596)
estimated from a hyperinsulinemic euglycemic clamp were measured in non-diabetic offspring of type 2 diabetic patients
from five European populations. Assuming an additive genetic model the diabetes-associated major C-allele of rs4607103
near ADAMTS9 associated with reduced insulin-stimulated glucose uptake (p=0.002) during a hyperinsulinemic euglycemic
clamp. However, following intravenous and oral administration of glucose serum insulin release was increased in individuals
with the C-allele (p=0.003 and p=0.01, respectively). A meta-analyse combining clamp and IVGTT data from a total of 905
non-diabetic individuals showed that the C-risk allele associated with decreased insulin sensitivity (p=0.003) and increased
insulin release (p=0.002). The major T-allele of the intronic JAZF1 rs864745 conferring increased diabetes risk was associated
with increased 2
nd phase serum insulin release during an IVGTT (p=0.03), and an increased fasting serum insulin level
(p=0.001). The remaining variants did not show any associations with insulin response, insulin sensitivity or any other
measured quantitative traits.
Conclusion: The present studies suggest that the diabetogenic impact of the C-allele of rs4607103 near ADAMTS9 may in
part be mediated through decreased insulin sensitivity of peripheral tissues.
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Introduction
Type 2 diabetes is a multifactorial disease caused by complex
interactions between multiple environmental factors and common as
well as rare expressions of genetic susceptibility variants. Candidate
gene studies and genome wide association (GWA) studies had until
early 2008 identified 11 type 2 diabetes loci [1–5]. A meta-analysis
combining three GWA studies including a total of 10,128 individuals,
followed by an extensive replication in 56,975 participants was
reported [6]. This study identified six previously unknown loci
reaching genome-wide significance levels of association with type 2
diabetes. The most significant variants in the regions were the
rs864745 in intron 1 of JAZF1, rs12779790 between CDC123 and
CAMK1D, rs7961581 between TSPAN8 and LGR5, rs7578597 in
exon 24 of THADA, rs4607103 near ADAMTS9 and rs10923931 in
intron 5 of NOTCH2 [6]. Little is known about the function of the
encoded gene products in relation to the pathophysiology and
molecular pathogenesis of type 2 diabetes. However, three of these
variants, JAZF1 rs864745, CDC123/CAMK1D rs12779790, and
TSPAN8 rs7961581, have in a population-based study of 4,516
glucose-tolerant middle aged Danes, shown association with a wide
range of measures of insulin release derived from an oral glucose
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Homozygous carriers of the minor diabetes-associated G-allele of the
CDC123/CAMK1D rs12779790 showed an 18% decrease in
insulinogenic index, an 18% decrease in corrected insulin response
(CIR), and a 13% decrease in the ratio of area under the serum
insulin and plasma glucose curves during an OGTT (AUC-insulin/
AUC-glucose) [7]. Carriers of the diabetes-associated T-allele of
JAZF1 rs864745 had an allele dependent 3% decrease in BIGTT-
AIR [7]. Furthermore, the diabetes-associated C-allele of TSPAN8
rs7961581 associated with decreased levels of CIR, AUC-insulin/
AUC-glucose ratio, and the insulinogenic index [7]. The remaining
three variants did not associate with the OGTT- derived traits or
estimates of insulin resistance [7]. Also a study among 1,317 Northern
Indians found a reduced insulin secretion following OGTT among
individuals carrying the CDC123/CAMK1D rs12779790 risk G-allele
[8]. These findings were, however, not replicated in a subsequent
study among 1,578 German individuals who underwent an OGTT
[9]. In the same study the diabetes-related C-allele of ADAMTS9
rs4607103 associated weakly with insulin resistance when estimated
by homeostasis model assessment of insulin resistance (HOMA-IR).
Furthermore, a non-significant tendency to association with insulin
resistance estimated from a euglycemic-hyperinsulinemic clamp
performed in a subgroup of 513 subjects was reported [9]. Given
the inconsistency of these previous findings, the aim of the present
study was to examine the possible impact of the type 2 diabetes
predisposing variants in or near JAZF1, CDC123/CAMK1D,TSPAN/
LGR5, THADA, ADAMTS9,a n dNOTCH2 loci on pancreatic beta-
cell function and insulin sensitivity in non-diabetic European
offspring of type 2 diabetic patients, who had been examined with
an OGTT and an intravenous glucose-tolerance test (IVGTT). In a
subset of 596 of the study participants the insulin sensitivity of
peripheral tissues was characterized by applying a euglycemic-
hyperinsulinemic clamp.
Methods
Subjects
The study included healthy non-diabetic offspring who had one
parent with known type 2 diabetes and the other parent with no
family history of type 2 diabetes and/or a normal response to an
OGTT. The family probands were selected from five white
European populations (the EUGENE2 Consortium study popu-
lations). Altogether DNA from 849 non-diabetic offspring was
available for examination: Danes (n=253), Finns (n=217),
Germans (n=149), Italians (n=130), and Swedes (n=100).
Clinical and biochemical characteristics of the study population
are shown in Table S1. The 149 German offspring included in the
present study sample were also part of a published study [9]. The
meta-analysis in the present study only included these individuals
once.
The participants gave informed written consent, and the study
protocols were approved by each center by the local ethical
committees: Ethics Committee of the University of Kuopio and
Kuopio University Hospital, Finland. Comitato di Bioetica -
Azienda Ospedaliera ‘‘Mater Domini’’ & Facolta ` di Medicina e
Chirurgia, Italy. Ethics Committee of the University of Gothen-
burg,Sweeden. Ethik-Kommission der Medizinischen Fakulta ¨t der
Universita ¨t Tu ¨bingen, Germany and Ethical Committee of
Copenhagen, Denmark and in accordance with the principles of
the Declaration of Helsinki II.
Physiology and biochemistry
All study centres followed the same protocol and study
participants were examined on two immediate occasions. On the
first occasion fasting blood samples were drawn after 12 hours of
fasting followed by an OGTT (75 g of glucose) to evaluate glucose
tolerance status and OGTT-related serum insulin release; samples
for measurements of plasma glucose and serum insulin were drawn
at 0, 30, 90, and 120 min during the OGTT. On the second
occasion an IVGTT was performed after 12 hours of fasting to
determine the first- and second-phase serum insulin release. A
bolus of glucose (300 mg/kg in a 50% solution) was given within
30 seconds into the antecubital vein. Blood sampling during
IVGTT was done as reported [10]. In a subset of 596 participants
the insulin sensitivity of peripheral tissues was measured applying a
euglycemic-hyperinsulinemic clamp as detailed [10].
Plasma glucose was measured by the same glucose oxidative
method in the different centers and determined by standard
laboratory methods [11]. Because serum insulin was measured
applying different methods (except for the Gothenburg centre
having their insulin measured in Tubingen), the assay applied in
Tubingen (micro-particle enzyme immunoassay; Abbott Labora-
tories, Tokyo, Japan) was selected as a reference assay. Each of the
centers in Catanzaro, Copenhagen and Kuopio sent about 100
fasting and post-glucose challenge plasma insulin samples for
parallel analysis to the Tubingen laboratory. Serum insulin levels
from these three centers were converted by linear regression
analysis to serum insulin levels corresponding to the Tubingen
assay as previously reported in detail [11,12]. The first and second
phase serum insulin responses were calculated as the area under
the serum insulin curve after IVGTT by the trapezoidal method
including 0–10 min. and 10–60 min., respectively. Disposition
index was calculated as the first phase serum insulin response after
IVGTT multiplied by the M value obtained from the euglycemic-
hyperinsulinemic clamp. HOMA-IR was calculated as (fasting
serum insulin (pmol/l) ? fasting plasma glucose (mmol/l))/22.5.
Insulinogenic index, the corrected insulin response (CIR), the ratio
of area under the serum-insulin and plasma-glucose curves during
an OGTT (AUCinsulin/AUC-glucose) and BIGTT-AIR were
calculated as previously described [7].
Anthropometrics
Height and body weight were measured in light indoor clothes
and without shoes, and BMI was calculated as weight (kg)/
(height(m))
2. Waist circumference was measured in the upright
position midway between the iliac crest and the lower costal
margin.
Genotyping of DNA isolated from leucocytes. The overall
genotyping success rates were .96% for all variants except for
CDC123/CAMK1D where a 90% genotyping success rate was
obtained. When examining 4.5% of the total samples in duplicate
the genotyping error rate was 0% for all variants. All genotype
distributions obeyed Hardy-Weinberg equilibrium (p.0.05).
Genotyping of the polymorphisms were performed applying the
TaqMan Allelic Discrimination Assay (Applied Biosystems, Foster
City, CA, USA).
Statistical analyses
Analyses were performed using Statistical Package for Social
Science (SPSS Inc., Chicago, IL, USA) version 14.0 and RGui
version 2.6.1 (http://www.r-project.org). The results for continu-
ous variables are given as means6SD. A p-value,0.05 was
considered to be significant. Serum insulin levels were logarith-
mically transformed prior to statistical analysis. Linear mixed
model analysis was applied to adjust for confounding factors. For
the linear mixed model analysis centre and pedigree (coded as a
family number) were included as random factors, sex as fixed
factors, and age, body mass index (BMI) and genotype were added
ADAMTS9 and Insulin Resistance
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multiple testing have not been performed. Based on 95%
confidence interval of the estimates of the effect size, we can in
the current study exclude effect sizes pr allele above 14% for
insulin sensitivity, above 21% for disposition index, above19% for
1
st phase insulin secretion and above 17% for 2
nd phase insulin
secretion including all variants. The meta-analysis was performed
using effect size estimates and SE derived from a mixed model (for
the present study) and a linear regression analysis (the German
study). These effects were based on log10 transformed traits. Both
fixed effect (weight of studies estimated using inverse variance) and
random effect (weight of studies estimated using DerSimonian-
Laird method) meta-analysis were applied [13]. The meta-analysis
was adjusted for sex, age and BMI.
Results
The major C-risk allele of rs4607103 near ADAMTS9,
conferring increased risk of type 2 diabetes, associated with
increased fasting plasma glucose levels (p=0.007) and a reduced
insulin-stimulated glucose uptake during a euglycemic-hyperinsu-
linemic clamp (p=0.002) (Table 1). The C-risk allele also showed
statistically significant associations with increased levels of serum
insulin at 30 min after oral ingestion of glucose (p=0.01) as well as
with increased first and second phase serum insulin release as
estimated from an IVGTT (p=0.003 and p=0.009) (Table 1).
The ADAMTS9 rs4607103 C-risk allele did not influence the
values of disposition index (Table 1).
Clamp and IVGTT derived measures of insulin sensitivity and
release (M-value, disposition index, 1
st and 2
nd phase insulin) were
also examined in meta-analyses (Figure 1). The ADAMTS9
rs4607103 C-allele associated with a decreased M-value in a fixed
effect meta-analysis (20.024, 95%CI [20.0402;20.008]) and
showed borderline association with decreased M-value in a random
effect meta-analysis (20.022, 95% CI [20.0443;20.0001]). The C-
allele also associated with increased 1
st phase insulin response
(0.047, 95%CI [0.017;0.077] (Random) and (0.047, 95%CI
[0.017;0.077] (Fixed)) and 2
nd phase insulin secretion (0.037,
95%CI [0.011;0.063] (Random) and 0.037, 95%CI [0.011;0.063]
(Fixed)). The C-allele did not associate with disposition index in the
meta-analysis (0.007, 95%CI [20.053;0.067] (Random) and 0.037,
95%CI [20.0153;0.067] (Fixed)). Heterogeneity was examined by
Q-test for all traits and none was observed.
The major diabetogenic T-allele of JAZF1rs864745 was associated
with increased levels of fasting serum insulin (p=0.001) (Table 2).
Also, second phase levels of serum insulin following intravenous
glucose administration was higher among the T-allele carriers
(p=0.03). In the meta-analyse the T-allele also associated with
increased 2
nd phase insulin secretion (0.03, 95%CI [0.003;0.049]
(Random) and 0.03, 95%CI [0.003;0.05] (Fixed) (Table S6). The
minor risk allele of the CDC123/CAMK1D rs12779790 variant was
nominally associated with elevated fasting serum insulin additive
model: p=0.07 (Table S4) and recessive model: p=0.05 (adjusted for
sex, age, BMI and fasting plasma glucose).
No effect on estimates of serum insulin release or insulin
sensitivity was observed for the NOTCH2 rs10920931, the TSPAN8
Table 1. Quantitative- and metabolic-characteristics of 819 non-diabetic offspring stratified according to the genotype of
ADAMTS9 rs4607103.
Genotype CC CT TT PAdditive
Quantitative characteristics
n (men/women) 413 (181/232) 343 (138/205) 63 (26/37)
Age ( years) 40693 9 693 9 610
BMI (kg/m
2) 26.864.9 26.565.1 26.164.7 0.2
Waist (cm) 90613 86614 88613 0.1
OGTT
Plasma glucose (mmol/l)
Fasting 5.160.5 5.060.5 4.960.5 0.007
30 - min OGTT related 8.361.8 8.162.0 8.162.0 0.3
120 - min OGTT related 6.361.6 6.161.5 6.161.5 0.1
Serum insulin (pmol/l)
Fasting 51637 50676 47630 0.5
30 - min OGTT related 4106266 3446200 3566218 0.01
120 - min OGTT related 3526308 2856216 2976234 0.2
IVGTT
Serum insulin (pmol/l?min)
1
st phase insulin secretion 3,61862,723 3,17562,596 2,66261,971 0.003
2
nd phase insulin secretion 11,707611,136 10,29669,203 7,93365,815 0.009
Clamp (n=596)
M value (umol/kg/min) 39.3616.3 43.7616.4 44.2616.8 0.002
Disposition index (pmol/l?min)x(umol/kg/min) 127,4846122,255 117,791681,103 104,416669,374 0.95
Risk allele is denoted in bold. Data are mean6standard deviation. Unadjusted values of serum insulin and derived indices were logarithmically transformed by log10
before statistical analysis. P-values were calculated assuming an additive model adjusted for age and sex (BMI and waist), or age, sex, and BMI (all other traits). Indices of
insulin release, M value and disposition index were calculated as described in Methods.
doi:10.1371/journal.pone.0007236.t001
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additive model (Table S2, S3, S4, S5). Similarly, no associations
between genotypes and serum insulin release or insulin sensitivity
were found when applying recessive and dominant models (data
not shown).
Applying additive, dominant and recessive genetic models,
respectively, we found no associations to insulinogenic index, the
corrected insulin response (CIR), the ratio of area under the
serum-insulin and plasma-glucose curves during an OGTT
(AUCinsulin/AUC-glucose) and BIGTT-AIR for CDC123/
CAMK1D rs12779790, JAZF1 rs864745, and TSPAN8 rs7961581
(data not shown).
Discussion
In the present study sample of Europeans, enriched in inherited
susceptibility to type 2 diabetes, we show that the common
diabetes-related C allele of rs4607103 at chromosome 3p14.3-2
upstream of ADAMTS9 is associated with a decrease in insulin
sensitivity of peripheral tissues, as estimated from a euglycemic-
hyperinsulinemic clamp. This impairment of insulin sensitivity
occurred in the presence of an increase in serum insulin levels in
response to intravenous and oral glucose loads. As expected, no
difference in disposition index was observed in this non-diabetic
high-risk study population of offspring of type 2 diabetes patients.
Accordingly, our data indicate that individuals at risk of
developing type 2 diabetes at this early stage of disease progression
can compensate for the increased insulin resistance by raising
insulin release upon glucose stimulation whereas a progressive loss
of beta cell function in the presence of progressive insulin
resistance will likely over time lead to a decline in glucose
tolerance. Thus, our findings suggest that rs4607103 near
ADAMTS9 may after PPARG Pro12Ala [14,15] be the second
gene locus conferring risk of type 2 diabetes due to insulin
resistance. Interestingly, a recent study of 1,578 Germans reported
nominally significant association of the diabetes-related C allele of
rs4607103 with an increase in OGTT-derived surrogate measures
of insulin resistance [9]. In the same study a subgroup of 513
subjects were examined applying the euglycemic-hyperinsulinemic
clamp. Here carriers of the C-allele of rs4607103 showed a trend
for having reduced insulin sensitivity [9], a finding which is in line
with the present clamp measurements in the larger study
population. We performed meta-analyses to estimate the com-
bined effect of ADAMTS9 rs4607103 on clamp and IVGTT results
of insulin sensitivity and release in the two studies. When testing
for heterogeneity between the German and the present study in
the meta-analyses none was found. Thus the fixed effect model can
be applied on these meta-analyses. However, it should be
Figure 1. Estimates of effects for the diabetes-associated major C-allele of rs4607103 near ADAMTS9 (based on log transformed
traits and adjusted for sex, age and BMI) of the variants with 95% confidence. A) M value; B) Disposition Index; C) 1
st phase insulin
secretion and D) 2
nd phase insulin secretion. The black diamonds represent the combined and weight (using the DerSimonian-Laird method) effects
of the studies. The grey diamonds represent the combined and weight (using inverse variance) effects of the studies.
doi:10.1371/journal.pone.0007236.g001
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including less than 10 studies is low [16]. The meta-analyses
support our finding of an association between ADAMTS9 and
decreased insulin sensitivity as well as increased insulin secretion.
The lack of a strong effect on insulin sensitivity of rs4607103 in the
German study could be explained by the fact that this study
population included only 68% with a family history of type 2
diabetes in contract to the present study where all individuals were
relatives which mostly likely enriches the inherited susceptibility to
type 2 diabetes. The molecular mechanisms behind the effect of
ADAMTS9 on peripheral insulin action and risk of diabetes are
unknown. ADAMTS9 is a member of the ADAMTS (a disintegrin
and metalloproteinase with thrombospondin motifs) protein family
which has been implicated in the cleavage of proteoglycans [17],
the control of organ maturation and development [18] and
inhibition of angiogenesis [19]. ADAMTS9 is highly expressed in
all fetal tissues and in a number of adult tissues where it is
abundantly expressed in heart and skeletal muscle [19]. This
observed ADAMTS9 expression pattern may be of relevance for
our finding of impaired insulin sensitivity of rs4607103 C-allele
carriers, as the euglycemic hyperinsulinemic clamp technique
primarily measures insulin sensitivity of skeletal muscle. Obviously,
prospective studies are needed to establish that a primary
diabetogenic effect of ADAMTS9 rs4607103 is mediated by a
decrease in insulin sensitivity of peripheral tissues.
Our study of JAZF1 rs864745 showed that the major T-allele
risk carriers had increased fasting serum insulin levels and slightly
elevated 2
nd phase insulin secretion after an intravenous glucose
load and the meta-analysis support this finding. We did not
observe any difference in circulating serum insulin levels after an
oral glucose load. In the initial GWA meta-analysis the JAZF1
variant showed the strongest association with type 2 diabetes [6]
and the same variant has subsequently shown association with
decreased BIGTT-AIR an estimate of serum insulin release
following an OGTT in middle-aged Danes [7]. The reasons for
the discrepancy between the previous and the present quantitative
trait study are unknown but may be due to ascertainment
differences as the previous report is a study of the general
population while the current investigation is focused on first degree
offspring of type 2 diabetes patients known to be insulin resistant
and diabetes-prone. Very little is known about the biological
function of JAZF1 but it is established that it is expressed in
multiple tissues including pancreas, brain, thalamus, liver, uterus,
endometrial and prostate and the gene encodes a nuclear protein
with three C2H2-type zinc fingers. The protein functions as a
transcriptional repressor of an orphan nuclear receptor (NR2C2)
[20] and chromosomal aberrations in the JAZF1 region associate
with endometrial stromal tumors [21].
The remaining four variants; THADA rs7578597, TSPAN8
rs7961581, NOTCH2 rs10923931 and CDC123/CAMK1D
rs12779790 did not associate with estimates of serum insulin
release or insulin sensitivity in the examined non-diabetic
Europeans neither alone or in a meta-analysis of clamp and
IVGTT derived traits. This finding may appear to be contrasting
to findings in our recent study of 4,516 middle-aged glucose-
tolerant individuals of the population-based Inter99 cohort [7]. In
Table 2. Quantitative- and metabolic-characteristics of 820 non-diabetic offspring of type 2 diabetes patients, stratified according
to genotype of JAZF1 rs864745.
Genotype TT TC CC PAdditiv
Quantitative characteristics
n (men/women) 244 (95/149) 392 (169/223) 184 (81/103)
Age6years 38694 0 610 4069
BMI6kg/m
2 26.465.0 26.664.8 26.765.5 0.8
Waist6cm 88613 89613 89614 0.9
OGTT
Plasma glucose (mmol/l)
Fasting 5.160.5 5.160.5 5.060.5 0.06
30 - min OGTT related 8.161.9 8.361.9 8.261.9 0.6
120 - min OGTT related 6.361.5 6.361.6 6.161.4 0.2
Serum insulin (pmol/l)
Fasting 51633 53674 43629 0.001
30 - min OGTT related 3926258 3816236 3606226 0.09
120 - min OGTT related 3446311 3206289 3026244 0.2
IVGTT
Serum insulin (pmol/l?min)
1
st phase insulin secretion 3,25362,306 3,51862,812 3,11262,615 0.2
2
nd phase insulin secretion 11,25269,843 10,931610,186 9,87369,939 0.03
Clamp n=596
M value (umol/kg/min) 42618 41616 41616 0.9
Disposition index (pmol/l?min) (umol/kg/min) 113,481662,700 125,198690,858 122,3976154,445 0.8
Risk allele is denoted in bold. Data are mean6standard deviation. Unadjusted values of serum insulin and derived indices were logarithmically transformed by log10
before statistical analysis. P-values were calculated assuming an additive model adjusted for age and sex (BMI and waist), or age, sex, and BMI (all other traits). Indices of
insulin release, M value and disposition index were calculated as described in Methods.
doi:10.1371/journal.pone.0007236.t002
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between the CDC123 and the CAMK1D and in the TSPAN8 locus
associated with a range of OGTT-based surrogate measures of
serum insulin release [7]. The significance of the CDC123/
CAMK1D rs12779790 variant association resisted correction for
multiple testing while it was concluded that the association of
rs7961581 near TSPAN8 needed further testing in independent
study samples [7]. The reason for non-replication of the Inter99
study findings in the present EUGENE2 study may be related to
lack of statistical power to detect the OGTT derived measures of
insulin sensitivity and beta-cell function. Based on the effect sizes
of the Inter99 study, it was estimated that ,6,100 and 3,900
subjects, respectively, were needed to achieve 80% statistical
power to replicate associations of CDC123/CAMK1D rs12779790
with insulinogenic index (recessive model), and rs7961581 near
TSPAN8 with insulinogenic index (dominant model) [7].
In conclusion, the present studies of non-diabetic Europeans
suggest that the diabetogenic impact of the C-allele of rs4607103
near ADAMTS9 may in part be mediated through decreased
insulin sensitivity of peripheral tissues.
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Estimates of effects for the diabetogenic risk-allele (based on log 10
transformed traits and adjusted for sex, age and BMI) of the
variants with 95% confidence interval.
Found at: doi:10.1371/journal.pone.0007236.s006 (0.08 MB
DOC)
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